Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Revance Therapeutics Inc.

www.revance.com

Latest From Revance Therapeutics Inc.

Mylan Prepares For US Trastuzumab Entry

Mylan is preparing to launch a trastuzumab biosimilar in the US, while progress of developing bevacizumab and aflibercept biosimilars continues. Insulin aspart and glargine are also in Mylan’s pipeline.

Biosimilars Launches

Allergan’s Botox Gains Continue, Pipeline Progresses Ahead Of AbbVie Merger

Key Allergan drugs performed well in Q3 and pipeline programs are approaching milestones as AbbVie says its $63bn acquisition of the company remains on track to close early next year.

Sales & Earnings Business Strategies

Mylan Gets Until April 2020 To Decide On Biosimilar Botox Collaboration With Revance

Revance has amended its agreement with Mylan to collaborate on a rival version of Botox to give Mylan more time to decide on whether it wants to continue developing the biosimilar. In turn, Mylan has agreed to pay $5m to Revance for the extended deadline.

Deals Biosimilars

Good News For AbbVie: Allergan's Q2 Sales Exceed Expectations, Including Behemoth Botox

AbbVie is buying Allergan for its product sales, both to increase its own revenues and to fund future R&D and business development, so Allergan's Q2 gains are good news.

Sales & Earnings Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
      • Topical Delivery
  • Therapeutic Areas
  • Dermatology
  • Gynecological, Urological
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Essentia Biosystems Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Revance Therapeutics Inc.
  • Senior Management
  • Mark J Foley, Pres. & CEO
    Tobin Schilke, CFO
    Abhay Joshi, PhD, COO
    Taryn Conway, VP, Mktg.
  • Contact Info
  • Revance Therapeutics Inc.
    Phone: (510) 742-3400
    7555 Gateway Blvd.
    Newark, CA 94560
    USA
UsernamePublicRestriction

Register